Recent clinical trials in hypertension report more deaths due to coronary heart disease in mild hypertensives who received aggressive antihypertensive drug therapy and achieved better blood pressure control. Subset analyses of these trials suggest that diuretic therapy may have contributed to this outcome, possibly through a reduction in serum potassium or an elevation in serum lipids. Because of this, patients with an abnormal pretreatment electrocardiogram, history of myocardial infarction, unstable coronary heart disease, or diuretic-induced hyperlipidemia or hypokalemia unresponsive to management are candidates for alternative antihypertensive agents. A review of the literature suggests that most of the currently available β-blockers, the α1-antagonist prazosin, the angiotensin-converting enzyme inhibitor captopril, and the vasodilator hydralazine are effective alternatives to thiazide therapy in the initial management of hypertension and are recommended for particular subgroups of patients. Monotherapy with the centrally and peripherally acting sympatholytic agents is not recommended because of the frequent side effects encountered and the inferior hypotensive efficacy reported. Calcium channel blocking agents also appear to be suitable alternatives to thiazides in hypertension, but more experience with these is needed. Alternative pharmacologic agents may be selected on the basis of age, and, to a lesser extent, race.
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967; 202: 1028–34.
2.
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment of morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970; 213: 1143–52.
3.
Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA1979; 242: 2562–71.
4.
SmithWM.Treatment of mild hypertension. Circ Res1977; 40 (Suppl 1): 198–105.
5.
Management committee. The Australian Therapeutic Trial in Mild Hypertension. Lancet1980; 1: 1261–7.
6.
HelgelandA.Treatment of mild hypertension: a five year controlled drug trial. Am J Med1980; 69: 725–32.
MoserM.Insurance premium reductions, a motivating factor in long-term hypertensive treatment. JAMA1984; 251: 756–7.
9.
RelmanAS.Mild hypertension: no more benign neglect. N Engl J Med1980; 302: 293–4.
10.
HolmeI.HelgelandA.HjermanI.LerenP.Lund-LarsenPG.Treatment of mild hypertension with diuretics. JAMA1984; 251: 1298–9.
11.
Multiple Risk Factor Intervention Trial Research Group. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol1985; 55: 1–15.
12.
McAlisterNH.Should we treat mild hypertension. JAMA1983; 249: 379–82.
13.
FriesED.Should mild hypertension be treated. N Engl J Med1982; 307: 306–9.
14.
RamCVS.Should mild hypertension be treated?Ann Intern Med1983; 99: 403–5.
15.
KaplanNM.Mild hypertension, when and how to treat. Arch Intern Med1983; 143: 255–9.
16.
MoserM.Clinical trials, diuretics and the management of mild hypertension. Arch Intern Med1984; 144: 789–92.
17.
KaplanNM.Response to Dr. Moser's commentary. Arch Intern Med1984; 1044: 792–3.
18.
DustanHpChobanianAvFalknerB.The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med1984; 144: 1045–57.
19.
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. JAMA1982; 248: 2004–11.
20.
Medical Research Council Working Party on Mild to Moderate Hypertension. Ventricular extrasystoles during thiazide treatments substudy of MRC Mild Hypertension Trial. Br Med J1983; 287: 1249–53.
21.
HollandObNixonJvKuhnertL.Diuretic-induced ventricular ectopic activity. Am J Med1981; 70: 762–8.
22.
PapademetriouV.FletcherR.KhatriImFriesED.Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium connection on cardiac arrhythmias. Am J Cardiol1983; 52: 1017–22.
RamCvsGarrettBnKaplanNM.Moderate sodium restriction and various diuretics in the treatment of hypertension: effects of potassium wastage and blood pressure control. Arch Intern Med1981; 141: 1015–9.
27.
VanbrummelerP.SchalekampM.DegraeffJ.Influence of sodium intake on hydrochlorothiazide-induced changes in blood pressure, serum electrolytes, renin and aldosterone in essential hypertension. Acta Med J1978; 204: 151–7.
28.
CranstonWiJuel-JensenBeSemmenceAmEffects of oral diuretics on raised arterial pressure. Lancet1963; 2: 966–70.
29.
DegnbolB.DorphS.MarnerT.The effects of different diuretics on elevated blood pressure and serum potassium. Acta Med Scand1973; 193: 407–10.
30.
BerglundG.AndersonO.Low doses of hydrochlorothiazide in hypertension. Eur J Clin Pharmacol1976; 10: 177–82.
31.
MatersonBjOsterJRMichaelUF.Dose response to chlorthalidone in patients with mild hypertension. Clin Pharmacol Ther1978; 24: 192–8.
32.
GrimmRhLeonAsHunninghaneDB.Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann Intern Med1981; 94: 7–11.
33.
GoldmanAiSteeleBwSchnopenHW.Serum lipoprotein levels during chlorthalidane therapy. A Veterans Administration-National Heart, Lung and Blood Institute Cooperative Study on antihypertensive therapy: mild hypertension. JAMA1980; 244: 1691–5.
34.
AmesRpHillP.Antihypertensive therapy and the risk of coronary heart disease. J Cardiovasc Pharmacol1982; 4 (Suppl 2): 2065–125.
35.
LasserNlGranditsG.CaggiulaAW.Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. Am J Med1984; 76: 52–66.
36.
InsullW.Coronary risk handbook: estimating the risk for coronary heart disease in daily practice. New York: American Heart Association Committee on Risk Reduction, 1973.
37.
BoehringerK.WeidmannP.MordasiniR.Menopause-dependent plasma lipoprotein alterations in diuretic-treated women. Ann Intern Med1982; 97: 206–9.
38.
WeidmannP.BiancheetM.MordasiniR.Effects of indapamide on various diuretics alone or combined with beta-blockers on serum lipoproteins. Curr Med Res Opin1983; 8 (Suppl 3): 123–34.
39.
AmesRpPeacockPB.Serum cholesterol during treatment of hypertension with diuretic drugs. Arch Intern Med1984; 144: 710–4.
40.
HelgelandA.HjermannI.LerenP.High-density lipoprotein cholesterol and antihypertensive drugs: The Oslo Study. Br Med J1978; 2: 403.
41.
ValimakiM.HarnoK.NakkilaEA.Serum lipoproteins and indices of glucose tolerance during diuretic therapy: a comparison between hydrochlorothiazide and piretanide. J Cardiovasc Pharmacol1983; 5: 525–30.
42.
WeidmannP.GerkenA.MordosiniR.Effects of antihypertensive therapy on serum lipoproteins. Hypertension1983; 5 (suppl II): 20–31.
43.
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Propranolol in the treatment of essential hypertension. JAMA1977; 237: 2303–10.
44.
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. I. Results of short-term titration with emphasis on racial differences in response. JAMA1982; 248: 1996–2003.
45.
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. JAMA1982; 248: 2004–11.
46.
BerglundG.AnderssonO.Beta-blockers or diuretics in hypertension: a six year follow-up of blood pressure and metabolic side effects. Lancet1981; 1: 744–7.
47.
PatersonJwDolleryCT.Effect of propranolol in mild hypertension. Lancet1966; 2: 1148–50.
48.
DawsonA.JohnsonBfSmithIkMunro-FaureAD.A comparison of the effects of labetalol, bendrofluazide and their combination in hypertension. Br J Clin Pharmacol1979; 8: 149–54.
49.
HorvothJsCatersonRjCollettP.Labetalol and bendrofluazide: comparison of their antihypertensive effects. Med J Aust1979; 1: 626–8.
50.
LorimerArBarbourMbLawrieTDV.An evaluation of the effect on resting and exercise blood pressure on some first line treatments in hypertension. Ann Clin Res1983; 15: 30–4.
51.
StokkelandOmLangvikK.LindsethDitlefsen Em.A comparative study of metoprolol and trichlormethiazide in hypertension. Curr Ther Res1975; 18: 755–68.
52.
PedersenOL.Comparison of metoprolol and hydrochlorothiazide as antihypertensive agents. Eur J Clin Pharmacol1976; 10: 381–5.
53.
FinnertyFA.Initial therapy of essential hypertension: diuretic or beta blockers?J Fam Pract1980; 11: 199–205.
54.
FagardR.AmeryA.DeplaenJF.Relative value of beta blockers and thiazides for initiating antihypertensive therapy: beta blockers on thiazides in hypertension. Acta Cardiol1976; 51: 411–26.
55.
PetrieJcGallowayDbWebsterJ.Atenolol and bendrofluazide in hypertension. Br Med J1975; 4: 133–5.
56.
MoserM.LunnJ.Comparative effects of pindolol and hydrochlorothiazide in black hypertensive patients. Angiology1981; 32: 561–6.
57.
ChalmersJ.HorvathJ.TillerD.BuneA.Effects of timolol and hydrochlorothiazide on blood-pressure and plasma renin activity. Lancet1976; 2: 328–31.
58.
HenninGrKarlbergBeOdar-CederlefI.Timolol and hydrochlorothiazide-amiloride in primary hypertension. Clin Pharmacol Ther1980; 28: 707–14.
59.
OparilS.Multiclinic double-blind evaluation of timolol combined with hydrochlorothiazide in essential hypertension. Curr Ther Res1980; 27: 527–37.
60.
TarriRcFrohlicEdDustonHP.Plasma volume changes with long-term beta-adrenergic blockade. Am Heart J1971; 82: 770–6.
61.
Veterans Administration Cooperative Study Group On Antihypertensive Agents. Efficacy of nadolol alone and combination with bendroflumethiazide and hydralazine for systemic hypertension. Am J Cardiol1983; 52: 1230–7.
62.
BassonW.MyburghDP.Synergism of a beta blocker and a diuretic in the once-a-day treatment of hypertension. J Clin Pharmacol1979; 19: 571–8.
63.
Medical Research Council Working Party on Mild to Moderate Hypertension. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet1981; 2: 539–42.
64.
BauerJhBrooksCsWeinsteinI.Effects of diuretics and propranolol on plasma lipoprotein lipids. Clin Pharmacol Ther1981; 30: 35–43.
65.
ShawJ.EnglandJdfHuaASP.Beta-blockers and plasma triglycerides (letter). Br Med J1978; 1: 986.
66.
SchauerI.SchauerU.RuehlingK.The effect of propranolol treatment on total cholesterol, HDL cholesterol, triglycerides, postheparin lipolytic activity and lecithin, cholesterol acyltransferase in hypertensive individuals. Artery1980; 8: 146–50.
67.
BeinartIwPearsonRmCrampDgHavardCWH.The effect of metoprolol on plasma lipids. Postgrad Med J1979; 58: 709–11.
68.
PasottiC.CapraA.FiorellaG.Effects of pindolol and metoprolol on plasma lipids and lipoproteins. Br J Clin Pharmacol1982; 13: 4355–95.
69.
DagTlSimpsonN.MetcalfeJ.PageRL.Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Br Med J1979; 1: 77–80.
70.
EliassonK.LinsLeRoessnerS.Serum lipoprotein changes during atenolol treatment of essential hypertension. Eur J Clin Pharmacol1981; 20: 335–8.
71.
CutlerR.Effect of antihypertensive agents on lipid metabolism. Am J Cardiol1983; 51: 628–31.
72.
Norwegian Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med1981; 304: 801–7.
73.
HjalmarsonA.ElmfeldtD.HerlitzJ.Effects on mortality of metoprolol in acute myocardial infarction. A double-blind randomized trial. Lancet1981; 1: 823–7.
74.
Cooperative Trial, National Heart, Lung and Blood Institute. The beta-blocker heart attack trial. JAMA1981; 246: 2073–4.
75.
FreisEdMatersonBjFlamenbaumW.Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. III. Evaluation of the renin-angiotensin system. Am J Med1983; 74: 1029–41.
76.
BuhlerFR.Age and cardiovascular response adaptation. Determinants of an antihypertensive treatment concept primarily based on beta-blockers and calcium entry blockers. Hypertension1983; 5 (suppl III) 94–100.
77.
BuhlerFRBurkartF.LutoldBE.Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol1975; 36: 653–8.
78.
ColucciWS.New developments in alpha-adrenergic receptor pharmacology: implications for the initial treatment of hypertension. Am J Cardiol1983; 51: 639–43.
79.
InouyeI.MassieB.BenowitzN.Monotherapy in mild to moderate hypertension: comparison of hydrochlorothiazide, propranolol and prazosin. Am J Cardiol1984; 55: 24–8A.
80.
BoliP.WoodAjSimpsonFO.Effects of prazosin in patients with hypertension. Clin Pharmacol Ther1976; 20: 138–41.
81.
O'ConnerDtPrestonRaSassoEH.Renal perfusion changes during treatment of essential hypertension: prazosin versus propranolol. J Cardiovasc Pharmacol1979; 1: 538–42.
82.
KirkendallWmHammondJjThomasJC.Prazosin and clonidine for moderately severe hypertension. JAMA1978; 240: 2553–6.
83.
NanivadekarAsKalkarnSS.Prazosin and methyldopa in hypertension. Practitioner1981; 225: 1327–9.
84.
JonesJvSteinerJM.Double-blind cross-over comparison of hydralazine and prazosin in hypertensive subjects on a beta adrenoceptor blocking agent (atenolol). Br J Clin Pharmacol1980; 10: 531–3.
85.
Mulvihill-WilsonJ.GrahamRmPettingerW.Comparative effects of prazosin and phenoxybenzamine on arterial blood pressure, heart rate, and plasma catecholamine in essential hypertension. J Cardiovasc Pharmacol1979; 1: 51–7.
86.
New Zealand Hypertension Study Group. Four to seven-year follow-up of patients on prazosin. N Z Med J1980; 92: 341–2.
87.
BauerJhJonesLbGaddyP.Effects of prazosin therapy on BP, renal function, and body fluid composition. Arch Intern Med1984; 144: 1196–200.
88.
LeichtenSbBaumgardnerB.Effects of chronic prazosin therapy on intermediary metabolism in diabetic patients. J Cardiovasc Med1981; 6 (spec suppl): 38–41.
LowensteinJ.Effects of prazosin on serum lipids in patients with essential hypertension: a review of the findings presented at the Satellite Symposium on Coronary Heart Disease Hypertension and Other Risk Factors. Milan, Italy, 1983. Am J Cardiol1984; 53: 21–3A.
91.
Veterans Administration Cooperative Study Group On Antihypertensive Agents. Captopril: evaluation of low doses, twice-daily doses and the addition of diuretic for the treatment of mild to moderate hypertension. Clin Sci1982; 63: 443–5s.
92.
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. Hypertension1983; 5 (suppl III): 139–44.
93.
GroelJtTadrosSsDreslinskiGrJenkinsAC.Long-term antihypertensive therapy with captopril. Hypertension1983; 5 (suppl III): 145–51.
94.
VlassesPhRotmenschHhSwansonBnMojaverianP.FergusonRK.Low-dose captopril: its use in mild to moderate hypertension unresponsive to diuretic treatment. Arch Intern Med1982; 142: 1098–101.
95.
GavrasH.BiollazJ.WaeberB.BrunnerHrGavrasI.DaviesRO.Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor. Lancet1981; 2: 543–6.
96.
WilkinsLhDustanHpWalkerJfOparilS.Enalapril in low-renin essential hypertension. Clin Pharmacol Ther1983; 34: 297–302.
97.
RotmenschHhVlassesPhFergusonRK.Resolution of captopril-induced rash after substitution of enalapril. Pharmacotherapy1983; 3: 131–3.
98.
AbramsWaDaviesRoFergusonRK.Overview: the role of the angiotensin converting enzyme inhibitors in cardiovascular therapy. Fed Proc1984; 43: 1314–21.
99.
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol1982; 14: 97–101S.
100.
DrayerJimWeberMA.Monotherapy of essential hypertension with a converting-enzyme inhibitor. Hypertension1983; 5 (suppl III): 108–13.
101.
ChrysantS.BrownR.KemDcBrownJ.Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril. Clin Pharmacol Ther1983; 33: 741–6.
102.
ChrysantSgDanisaK.KemDcDillardBlSmithWjFrohlichED.Racial differences in pressure, volume and renin interrelationships in essential hypertension. Hypertension1979; 1: 136–41.
103.
BrunnerHrGavrasH.WaeberB.Clinical use of an orally acting converting enzyme inhibitor: captopril. Hypertension1980; 2: 558–65.
104.
ColwillJmDuttonAmMorrisseyJ.YuPN.Alphamethyldopa and hydrochlorothiazide: a controlled study of their comparative effectiveness as antihypertensive agents. N Engl J Med1964; 271: 696–703.
105.
WilsonWrOkunR.TetreaultL.FallsN.Methyldopa and hydrochlorothiazide in primary hypertension: controlled clinical trial of drugs singly and in combination. JAMA1963; 185: 819–25.
106.
HansenJ.Alpha-methyl-dopa (Aldomet) in the treatment of hypertension: the effects on blood volume, exchangeable sodium, body weight and blood pressure. Acta Med Scand1968; 30: 536–41.
107.
MroczekWjDavidovM.FinnertyFA.Prolonged treatment with clonidine: comparative antihypertensive effects alone and with a diuretic agent. Am J Cardiol1972; 30: 536–41.
108.
OnestiG.SchwartzAbKimKeSwantzC.BrestAN.Pharmadynamic effects of a new antihypertensive drug, Catapres (ST-155). Circulation1969; 39: 219–28.
109.
SungPkSametP.YehBK.Effects of clonidine and chlorthalidone on blood pressure and glucose tolerance in hypertensive patients. Curr Ther Res1971; 13: 280–5.
110.
ParsonsWbMorledgeJA.Antihypertensive effects of a new imidazoline compound (clonidine) and chlorthalidone, individually and in combination. Am J Cardiol1970; 26: 258–61.
111.
DavidovM.KakaviatosN.FinnertyFA.Antihypertensive effects of an imidazoline compound. Clin Pharmacol Ther1967; 8: 810–5.
112.
HolmesB.BrogdenRnHeelRcSpeightTmAveryGS.Guanabenz: a review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs1983; 26: 212–29.
113.
WalkerBrDeitchMwSchneiderBeHareLE.Comparative antihypertensive effects of guanabenz and methyldopa. Clin Ther1981; 4: 275–84.
114.
HirvonenP.PorstiP.FrickMH.A comparison of guanabenz and methyldopa in hypertension. Curr Ther1980; 27: 197–204.
115.
WalkerBrDeitchMwGoldJaLeveyBA.Evaluation of guanabenz added to hydrochlorothiazide therapy in hypertension. J Int Med Res1982; 10: 131–9.
116.
GilmoreE.WeilJ.ChidseyC.Treatment of essential hypertension with a new vasodilator in combination with beta-adrenergic blockade. N Engl J Med1970; 282: 521–7.
117.
ZacestR.GilmoreE.Kock-WeserJ.Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade. N Engl J Med1972; 286: 617–22.
118.
SimonAcSafarMaLevensonJaKhederAmLevyBI.Systolic hypertension: hemodynamic mechanism and choice of antihypertensive treatment. Am J Cardiol1979; 44: 505–11.
119.
GottliebTbKatzFhChidseyCA.Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension: a comparative study of minoxidil and hydralazine. Circulation1972; 45: 571–82.
120.
FergusonRkRothenbergRjNiesAS.Patient acceptance of guanethidine as therapy for mild and moderate hypertension: a comparison with reserpine. Circulation1976; 54: 32–7.
121.
GuazziM.MagrinF.FiorentiniC.Role of the sympathetic nervous system in supporting cardiac function in essential arterial hypertension. Br Heart J1973; 35: 55–64.
122.
WeilJvChidseyCA.Plasma volume expansion resulting from interference with adrenergic function in normal man. Circulation1968; 37: 54–61.
123.
Ronnov-JessenV.HansenJ.Blood volume and exchangeable sodium during treatment of hypertension with guanethidine and hydrochlorothiazide. Acta Med Scand1969; 186: 255–63.
124.
BloomfieldDkCangianoJL.Guanadrel and guarethidine in hypertension. Clin Pharmacol Ther1970; 11: 200–4.
125.
NugentCaPalmerJdUesprungJJ.Guanadrel sulfate compared with methyldopa for mild and moderate hypertension. Pharmacotherapy1982; 2: 378–83.
126.
BuehlerFrHulthenUlKiowskiW.MuellerFbBolliP.The place of the calcium antagonist verapamil in antihypertensive therapy. J Cardiovasc Pharmacol1982; 4: S350–7.
127.
ErneP.BolliP.BertelO.Factors influencing the hypotensive effects of calcium antagonists. Hypertension1983; 5 (suppl II): 97–102.
128.
YamakodoT.OonishiN.KondoS.Effects of diltiazem on cardiovascular responses during exercise in systemic hypertension and comparison with propranolol. Am J Cardiol1983; 52: 1023–7.
129.
KleinW.BrandtD.VreckoK.HarringerM.Role of calcium antagonist in the treatment of essential hypertension. Circ Res1983; 52: 1174–81.
130.
DrebsR.Adverse reactions with calcium antagonist. Hypertension1983; 5 (suppl II): 125–9.
131.
BuhlerFrHulthenUlKiowskiW.BolliP.Greater antihypertensive efficacy of the calcium channel inhibitor verapamil in older and low renin patients. Clin Sci1982; 63: 4395–425.
